Gyre Therapeutics, Inc. (GYRE)
GYRE moved a median of +0.40% 30 minutes after news, and +0.16% by the close. How GYRE actually reacts to news — the realized, point-in-time move the market made, measured across 265 labeled events over the last three years with zero look-ahead.
GYRE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.35% | 56% | 261 |
| 30-min | +0.40% | 57% | 262 |
| 60-min | +0.25% | 56% | 264 |
| to close | +0.16% | 51% | 261 |
| Middle 50% of GYRE reactions | -1.19% to +2.70% |
|---|---|
| Median reaction (30-min) | +0.40% |
| Measured reactions | 265 |
Half of all Gyre Therapeutics, Inc. news events land between -1.19% and +2.70% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GYRE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GYRE's baseline. Nothing else.
Recent GYRE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Gyre Therapeutics to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | +0.47% | +1.10% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | +0.23% | -0.61% | |
| Form S-8 GYRE THERAPEUTICS, INC. | SEC filing · Form S-8 | SEC EDGAR | -1.81% | -0.46% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | -0.89% | |
| Form 10-Q GYRE THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.75% | — | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +1.56% | +4.06% | |
| Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.56% | +4.06% | |
| Form EFFECT GYRE THERAPEUTICS, INC. | SEC filing · Form EFFECT | SEC EDGAR | +2.06% | +0.66% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | -3.20% | |
| Gyre Therapeutics Appoints Three New Members to its Board of Directors | Press release | GlobeNewswire | -1.66% | -3.20% | |
| Form 8-K/A GYRE THERAPEUTICS, INC. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -0.92% | -1.99% | |
| Form S-3/A GYRE THERAPEUTICS, INC. | SEC filing · Form S-3 | SEC EDGAR | -2.05% | +0.16% | |
| GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm | Press release | ACCESS Newswire | +0.00% | +0.78% | |
| Form S-3 GYRE THERAPEUTICS, INC. | SEC filing · Form S-3 | SEC EDGAR | +1.96% | +0.00% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | +0.00% | |
| Form S-8 GYRE THERAPEUTICS, INC. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -1.65% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +1.47% | -4.14% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.80% | -4.66% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.81% | -1.22% | |
| Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment | Press release | GlobeNewswire | +0.81% | -1.22% | |
| Form 10-Q GYRE THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.47% | -4.19% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -7.04% | -10.51% | |
| Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update | Press release | GlobeNewswire | -7.04% | -10.51% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | +1.80% | |
| Form DEFA14A GYRE THERAPEUTICS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +0.71% | +1.80% | |
| Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company | Press release | GlobeNewswire | +0.71% | +1.80% | |
| Form ARS GYRE THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.57% | +0.39% | |
| Form DEF 14A GYRE THERAPEUTICS, INC. For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | +1.57% | +0.39% | |
| Form DEFA14A GYRE THERAPEUTICS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +1.57% | +0.39% | |
| GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm | Press release | GlobeNewswire | -0.49% | -1.98% | |
| Form 8-K/A GYRE THERAPEUTICS, INC. For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | +1.25% | |
| Form PRE 14A GYRE THERAPEUTICS, INC. For: Jun 10 | SEC filing · Form PRE | SEC EDGAR | +0.75% | +1.25% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Mar 22 | SEC filing · Form 8-K | SEC EDGAR | +1.96% | +2.03% | |
| Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment | Press release | GlobeNewswire | +1.89% | -0.13% | |
| Form 10-K GYRE THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.91% | -2.09% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +2.75% | -1.20% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +2.75% | -1.20% | |
| Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +2.75% | -1.20% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +1.40% | +6.96% | |
| Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline | Press release | GlobeNewswire | +1.40% | +6.96% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +3.80% | +6.88% | |
| Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting | Press release | GlobeNewswire | +3.80% | +6.88% | |
| Form 10-Q GYRE THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.18% | +3.80% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -1.65% | -0.82% | |
| Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.65% | -0.82% | |
| Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis | Press release | GlobeNewswire | +3.01% | +6.87% | |
| Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 | Press release | GlobeNewswire | +0.00% | -3.38% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +1.44% | +7.08% | |
| Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | +0.91% | +3.00% | |
| Form 8-K GYRE THERAPEUTICS, INC. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | +5.68% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GYRE section they belong to.
Where else GYRE is measured.
GYRE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Gyre Therapeutics, Inc.'s median reaction calculated?
Every labeled GYRE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 265 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 57% of GYRE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GYRE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.